Navigation Links
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
Date:7/14/2009

TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.

QI is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients who have failed conventional therapy. According to Mr. Chuck Broes, CEO of QI, "This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome."

The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen ("OFA"), or iLRP -- immature Laminin Receptor Protein, as a cancer antigen (a protein found on cancer cells that can be targeted by the body's own immune system) found in many tumor cell lines or fetal tissue, but absent on normal, healthy tissue. QI believes that the OFA antigen can serve as a unique, valuable and promising antigen for individualized breast cancer immunotherapy.

Centered in Mobile, AL, QI's clinical trial is designed around the use of QI's proprietary dendritic cell therapy, which employs OFA to recruit the patient's own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient's own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient's T-cells will locate the OFA found on the patient's cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.

About Quantum Immunologics

Quantum Immunologics, Inc. ("QI") is a research-driven biotechnology company that is pioneering discoveries in immunotherapy science. QI is dedicated to the research, development and production of technologies that focus on the treatments and diagnoses of cancer and other diseases related to the immune system. Leveraging an expansive pipeline of biopharmaceutical innovations, QI remains committed to advancing medicine with the ultimate goal of dramatically improving lives.

For more information about QI and its FDA-authorized trials, please visithttp://www.quantumimmunologics.com, or contact Investor Relations at (813) 849-7859.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    Contact:

    Timothy Schwiers
    Investor Relations
    813-849-7859

    Quantum Immunologics, Inc.
    2202 N. West Shore Blvd., Suite 200
    P.O. Box 20727
    Tampa, Florida 33623

This release was issued through eReleases(TM). For more information, visithttp://www.ereleases.com.


'/>"/>
SOURCE Quantum Immunologics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
2. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
3. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
6. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
7. Immunotherapy-Based Provisional Patents Mark Significant Discovery
8. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
9. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
10. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
11. iCardiac Reports Significant Revenue Growth and Profitability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a ... dedicated to the North American healthcare market. , Aerocom Healthcare, LLC will be ... The company will provide new pneumatic tube systems or expand existing systems within ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... and Unix visualization solutions today announced the addition of a powerful “Session Preview” ... to see the current state of the remote Linux desktop or other applications ...
(Date:2/3/2016)... 2016  Silk Therapeutics, Inc., today announced the closing of ... now raised a total of $10.25 million in Series A ... Series A2 round was led by existing investor The Kraft ... from new investors Lear Corporation and Highland Consumer Partners, as ... ; Richard Sackler , MD, with Summer Road, LLC; ...
(Date:2/3/2016)... ... 03, 2016 , ... ZeptoMetrix™ Corporation (ZMC), announced today the ... quality control of molecular assays targeting the Zika Virus. , “Our level of ... President and CEO of ZeptoMetrix, relayed to his Executive Team. “We need to ...
Breaking Biology Technology:
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... January 13, 2016 --> ... a new market report titled - Biometric Sensors Market - ... 2015 - 2023. According to the report, the global biometric sensors ... anticipated to reach US$1,625.8 mn by 2023, expanding at ... terms of volume, the biometric sensors market is expected ...
Breaking Biology News(10 mins):